Karin Jirstrom

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. ncbi Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study
    Liv Jonsson
    Department of Clinical Sciences, Pathology, Lund University, Skane University Hospital, 221 85 Lund, Sweden
    J Transl Med 9:114. 2011
  2. ncbi Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer
    Asa Ehlén
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skane University Hospital, Malmo, Sweden
    J Transl Med 8:78. 2010
  3. ncbi Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer
    Elton Rexhepaj
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Ireland
    Breast Cancer Res 10:R89. 2008
  4. ncbi Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
    Signe Borgquist
    Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden
    Breast Cancer Res 10:R79. 2008
  5. ncbi Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro
    Fiona Lanigan
    University College Dublin School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
    Breast Cancer Res 12:R59. 2010
  6. ncbi Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
    Donal J Brennan
    Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland
    BMC Cancer 10:125. 2010
  7. ncbi Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
    Elton Rexhepaj
    UCD Conway Institute, University College Dublin, Belfield, Ireland
    BMC Cancer 10:639. 2010
  8. ncbi Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray
    Elin Möllerström
    Department of Oncology, Institute of Clinical Sciences, Blå stråket 2, University of Gothenburg, SE 413 45 Goteborg, Sweden
    BMC Cancer 10:296. 2010
  9. ncbi Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study
    Wenjing Zhou
    Department of Surgical Science, Uppsala University, Uppsala, SE 75105, Sweden
    BMC Cancer 10:653. 2010
  10. ncbi Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
    Donal J Brennan
    Department of Pathology, Clinical Sciences, Lund University, Skane University Hospital, 221 85 Lund, Sweden
    Breast Cancer Res 13:R12. 2011

Collaborators

Detail Information

Publications46

  1. ncbi Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study
    Liv Jonsson
    Department of Clinical Sciences, Pathology, Lund University, Skane University Hospital, 221 85 Lund, Sweden
    J Transl Med 9:114. 2011
    ..In this study, the prognostic value of immunohistochemical RBM3 expression was assessed in incident cases of malignant melanoma from a prospective population-based cohort study...
  2. ncbi Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer
    Asa Ehlén
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skane University Hospital, Malmo, Sweden
    J Transl Med 8:78. 2010
    ..The aim of this study was to examine the prognostic value of RBM3 mRNA and protein expression in epithelial ovarian cancer (EOC) and the cisplatin response upon RBM3 depletion in a cisplatin-sensitive ovarian cancer cell line...
  3. ncbi Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer
    Elton Rexhepaj
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Ireland
    Breast Cancer Res 10:R89. 2008
    ..In the present article we describe the development of a novel approach for automatically quantifying oestrogen receptor (ER) and progesterone receptor (PR) protein expression assessed by IHC in primary breast cancer...
  4. ncbi Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer
    Signe Borgquist
    Center for Molecular Pathology, Department of Laboratory Medicine, Malmo University Hospital, Lund University, Malmo, Sweden
    Breast Cancer Res 10:R79. 2008
    ..In the present study, we examined the prognostic value of HMG-CoAR expression in a large cohort of primary breast cancer patients with long-term follow up...
  5. ncbi Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro
    Fiona Lanigan
    University College Dublin School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
    Breast Cancer Res 12:R59. 2010
    ..However, the clinical implications of Msx2 expression in breast cancer are unclear. The aims of this study were to investigate the potential clinical value of Msx2 as a breast cancer biomarker and to clarify its functional role in vitro...
  6. ncbi Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer
    Donal J Brennan
    Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland
    BMC Cancer 10:125. 2010
    ..In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer...
  7. ncbi Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
    Elton Rexhepaj
    UCD Conway Institute, University College Dublin, Belfield, Ireland
    BMC Cancer 10:639. 2010
    ..Here, we validate survivin CNR in a separate and extended cohort. Furthermore, we present new data suggesting that a low CNR may predict outcome in tamoxifen-treated patients...
  8. ncbi Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray
    Elin Möllerström
    Department of Oncology, Institute of Clinical Sciences, Blå stråket 2, University of Gothenburg, SE 413 45 Goteborg, Sweden
    BMC Cancer 10:296. 2010
    ..The aim of this study was to characterize the expression of the corresponding proteins in breast carcinoma and to determine their correlation with clinical outcome...
  9. ncbi Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study
    Wenjing Zhou
    Department of Surgical Science, Uppsala University, Uppsala, SE 75105, Sweden
    BMC Cancer 10:653. 2010
    ..However, the prognosis of basal-like ductal carcinoma in situ (DCIS) is still unknown. Our aim was to study the prognosis of basal-like DCIS in a large population-based cohort...
  10. ncbi Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
    Donal J Brennan
    Department of Pathology, Clinical Sciences, Lund University, Skane University Hospital, 221 85 Lund, Sweden
    Breast Cancer Res 13:R12. 2011
    ..Here, the predictive value of HMG-CoAR expression in relation to tamoxifen response was examined...
  11. ncbi Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival
    Björn Nodin
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, and Skåne Regional Laboratories, Malmo, Sweden
    J Ovarian Res 3:14. 2010
    ..Altered androgen hormone homeostasis and androgen receptor (AR) activity have been implicated in ovarian carcinogenesis but the relationship between AR expression in ovarian cancer and clinical outcome remains unclear...
  12. ncbi Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer
    Annika Jögi
    Department of Laboratory Medicine, Center for Molecular Pathology, Malmo University Hospital, Lund University, Malmo, Sweden
    Mod Pathol 22:1564-74. 2009
    ..49, 95% CI: 0.30-0.79, P=0.004). These data strongly indicate that nuclear RBM3 is an independent favorable prognostic factor in breast cancer, and seems to have a specific role in ER-positive tumors...
  13. ncbi Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer
    Helena Tassidis
    Department of Tumor Biology, Lund University, Malmo University Hospital, Malmo, Sweden
    Int J Cancer 126:2296-307. 2010
    ....
  14. ncbi Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up
    Lisa Rydén
    Department of Surgery, Institution of Clinical Sciences, Lund University Hospital, SE 221 85, Lund, Sweden
    Breast Cancer Res Treat 120:491-8. 2010
    ..High VEGFR2 expression, EGFR expression, and EGFR gene copy number were significantly correlated to TNB, supporting their role as putative candidate biomarkers for selection of targeted therapy in TNB...
  15. ncbi Anthropometric factors and ovarian cancer risk in the Malmö Diet and Cancer Study
    Jenny Brändstedt
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skane University Hospital, Malmo, Sweden
    Cancer Epidemiol 35:432-7. 2011
    ..To examine the associations of measured anthropometric factors, including general and central adiposity, with epithelial ovarian cancer (EOC) risk in the Malmö Diet and Cancer Study...
  16. ncbi Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
    Caroline Holm
    Division of Pathology, Department of Laboratory Medicine, Lund University, Malmo, Sweden
    J Natl Cancer Inst 98:671-80. 2006
    ..Here we studied associations between Pak1 expression and subcellular localization in tumor cells and tamoxifen resistance...
  17. ncbi HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors
    Signe Borgquist
    Department of Laboratory Medicine, Center for Molecular Pathology, Malmo University Hospital, Malmo, Sweden
    Int J Cancer 123:1146-53. 2008
    ..Moreover, estrogen related life-style and anthropometric factors might indeed regulate HMG-CoAR expression...
  18. ncbi A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen
    Sophie Lehn
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skane University Hospital, Malmo, Sweden
    Cell Cycle 10:956-62. 2011
    ....
  19. ncbi Stromal expression of ?-arrestin-1 predicts clinical outcome and tamoxifen response in breast cancer
    Katja Lundgren
    Department of Laboratory Medicine, Center for Molecular Pathology, Lund University, Malmo University Hospital, Malmo, Sweden
    J Mol Diagn 13:340-51. 2011
    ..Furthermore, CCND1 amplification was inversely correlated with tumor cell expression of ?-arrestin-1, indicating ARRB1 gene deletion in CCND1-amplified breast cancers...
  20. ncbi Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients
    Alexander Gaber
    Department of Laboratory Medicine, Lund University, Skane University Hospital, Center for Molecular Pathology, Malmo, Sweden
    BMC Cancer 10:498. 2010
    ..We further assessed the prognostic value of carcino-embryonic antigen in serum (s-CEA) and the interrelationship between s-TATI and TATI in tissue (t-TATI)...
  21. ncbi Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features
    Sophie Lehn
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, UMAS, Sweden
    Am J Pathol 177:2886-97. 2010
    ..This novel function of cyclin D1 illustrates the interplay between tumor proliferation and migration and may explain the attenuation of malignant behavior in breast cancers with high cyclin D1 levels...
  22. ncbi Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer
    Karolina Helczynska
    Center for Molecular Pathology, Department of Laboratory Medicine, University Hospital MAS, Malmo, Sweden
    Cancer Res 68:9212-20. 2008
    ..At prolonged hypoxia, HIF-2alpha remained accumulated, whereas HIF-1alpha protein levels decreased, in agreement with the oxygen level and time-dependent induction of HIFs recently reported in neuroblastoma...
  23. ncbi High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression
    Liv Jonsson
    Department of Clinical Sciences, Pathology, Lund University, Skane University Hospital, 221 85 Lund, Sweden
    Diagn Pathol 6:91. 2011
    ..The aim of this study was to examine the prognostic impact of immunohistochemical RBM3 expression in prostate cancer...
  24. ncbi p27Kip1 is a predictive factor for tamoxifen treatment response but not a prognostic marker in premenopausal breast cancer patients
    Maria Stendahl
    Center for Molecular Pathology, Lund University, Malmo University Hospital, Malmo, Sweden
    Int J Cancer 127:2851-8. 2010
    ..034). Our study suggests that p27 downregulation is associated with tamoxifen resistance in premenopausal breast cancer but is not linked to impaired prognosis...
  25. ncbi Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis
    Anna Dahlman
    Department of Clinical Sciences, Division of Urological Cancers, Lund University, Skane University Hospital, Malmo, Sweden
    Mod Pathol 24:708-19. 2011
    ....
  26. ncbi Anthropometric factors in relation to different tumor biological subgroups of postmenopausal breast cancer
    Signe Borgquist
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, University Hospital MAS, S 205 02 Malmo, Sweden
    Int J Cancer 124:402-11. 2009
    ..Furthermore, obesity was associated with tumors expressing several markers corresponding with low malignancy...
  27. ncbi ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
    Sofie Svensson
    Division of Pathology, Department of Laboratory Medicine, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Oncogene 24:4370-9. 2005
    ..Finally, patients with oestrogen receptor positive and ERK1/2 phosphorylated tumours also had an impaired tamoxifen response...
  28. ncbi Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer
    Anna Maria Larsson
    Center for Molecular Pathology, Department of Laboratory Medicine, University Hospital MAS, Malmo, Sweden
    Clin Cancer Res 15:5552-9. 2009
    ..In an attempt to understand these clinical data, we analyzed EPO and EPOR expression in breast cancer and evaluated EPOR as a putative prognostic and predictive marker in breast cancer patients treated with tamoxifen...
  29. ncbi Diet and body constitution in relation to subgroups of breast cancer defined by tumour grade, proliferation and key cell cycle regulators
    Signe Borgquist
    Division of Pathology, Department of Laboratory Medicine, Malmo University Hospital, S 205 02 Malmo, Sweden
    Breast Cancer Res 9:R11. 2007
    ....
  30. ncbi Breast tumours following combined hormone replacement therapy express favourable prognostic factors
    Signe Borgquist
    Department of Laboratory Medicine, Division of Pathology, Malmo University Hospital, Lund University, SE 20502 Malmo, Sweden
    Int J Cancer 120:2202-7. 2007
    ..We conclude that the use of CHRT is associated with an increased incidence of breast tumours with comparatively favourable prognostic factors...
  31. ncbi PKCalpha expression is a marker for breast cancer aggressiveness
    Gry Kalstad Lønne
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malmo University Hospital, SE 205 02 Malmo, Sweden
    Mol Cancer 9:76. 2010
    ..Protein kinase C (PKC) isoforms are potential targets for breast cancer therapy. This study was designed to evaluate which PKC isoforms might be optimal targets for different breast cancer subtypes...
  32. ncbi The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation
    Sandra Sernbo
    Department of Immunotechnology, Lund University, Lund, Sweden
    BMC Cancer 11:405. 2011
    ....
  33. ncbi RBM3-Regulated Genes Promote DNA Integrity and Affect Clinical Outcome in Epithelial Ovarian Cancer
    Osa Ehlén
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skane University Hospital, Malmo, Sweden
    Transl Oncol 4:212-21. 2011
    ..Furthermore, it is demonstrated that Chk1, Chk2, and MCM3 are poor prognostic markers in EOC...
  34. ncbi Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients
    Cecilia Magnusson
    Division of Cell and Experimental Pathology, Department of Laboratory Medicine, Lund University, SE 205 02 Malmo, Sweden
    Int J Cancer 129:9-22. 2011
    ..Our data indicate that low CysLT(1)R together with high CysLT(2)R expression levels might be useful parameters in prognostication and treatment stratification of breast cancer patients...
  35. ncbi High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients
    Maria Stendahl
    Department of Laboratory Medicine, Division of Pathology, , Lund University, Malm, Sweden
    Clin Cancer Res 12:4614-8. 2006
    ..Based on these findings, we suggest the implementation of a fractioned rather than dichotomized immunohistochemical evaluation of hormone receptors in clinical practice, possibly with greater emphasis on the PR than the ER...
  36. ncbi Plasma folate concentrations are positively associated with risk of estrogen receptor beta negative breast cancer in a Swedish nested case control study
    Ulrika Ericson
    Department of Clinical Sciences, Nutrition Epidemiology, Lund University, Malmo, Sweden
    J Nutr 140:1661-8. 2010
    ..The study contributes knowledge concerning folate's multifaceted role in cancer development. If replicated in other populations, the observations may have implications for public health, particularly regarding folic acid fortification...
  37. ncbi Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients
    Alexander Gaber
    Department of Clinical Sciences, Division of Pathology, Lund University, Skane University Hospital, Lund, Sweden
    Radiat Oncol 6:100. 2011
    ..In this study, we investigated the effects of neoadjuvant radiotherapy (RT) on concentrations of t-TATI and s-TATI in patients with rectal cancer...
  38. ncbi Molecular evolution of specific human antibody against MUC1 mucin results in improved recognition of the antigen on tumor cells
    Jonas Persson
    Department of Immunotechnology, Lund University, Lund, Sweden
    Tumour Biol 30:221-31. 2009
    ..Molecular evolution and specific fine-tuning thus have the potential to improve the performance of antibody specificities targeting tumor-associated epitopes on MUC1 mucin...
  39. ncbi Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma
    Sara Ek
    Department of Immunotechnology, CREATE Health, Biomedical Center, Lund University, and Department of Pathology, Lund University Hospital, Sweden
    Blood 111:800-5. 2008
    ....
  40. ncbi Chondroitin sulfate expression predicts poor outcome in breast cancer
    Katrin J Svensson
    Department of Clinical Sciences, Section of Oncology, Lund University, SE 221 85, Lund, Sweden
    Int J Oncol 39:1421-8. 2011
    ....
  41. ncbi Isolation and characterization of progenitor-like cells from human renal proximal tubules
    David Lindgren
    Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, SUS Malmö, Malmo, Sweden
    Am J Pathol 178:828-37. 2011
    ....
  42. ncbi Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study
    Sakarias Wangefjord
    Department of Clinical Sciences, Division of Pathology, Lund University, Skane University Hospital, 221 85 Lund, Sweden
    Biol Sex Differ 2:10. 2011
    ..abstract:..
  43. ncbi Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response
    Asa Kronblad
    Division of Pathology, Department of Laboratory Medicine, Lund University, , S- Malm, Sweden
    Int J Cancer 118:2609-16. 2006
    ....
  44. ncbi Cyclin E overexpression obstructs infiltrative behavior in breast cancer: a novel role reflected in the growth pattern of medullary breast cancers
    Pontus Berglund
    Division of Pathology, Department of Laboratory Medicine, Lund University, , Malm, Sweden
    Cancer Res 65:9727-34. 2005
    ....